Why Indonesian and Vietnamese Patients Choose China for CAR-T

CAR-T therapy is not yet commercially available in Indonesia or Vietnam. Patients who need CD19 CAR-T (for B-cell lymphoma or leukemia), BCMA CAR-T (for multiple myeloma), or Claudin18.2 CAR-T (satri-cel for gastric cancer — a leading cancer type in East and Southeast Asia) typically have three regional options:

OptionProsCons2026 Cost (USD)
SingaporeClosest to home; high English / Bahasa Indonesia / Vietnamese language coverage; JCI-accreditedCAR-T only available at 1-2 centers; mostly commercial pricing$280K – $400K
China7 approved products; commercial + trial pricing; multiple Tier-1 cities with direct flights from Jakarta / Ho Chi MinhMedical visa required for most patients (some nationalities visa-free)$30K – $151K
IndiaLowest commercial pricing globally; English widely spokenLimited BCMA / Claudin18.2 access; fewer approved products; travel via connecting flight$50K – $120K

All cost figures are 2026 estimates based on published data; final cost depends on hospital and clinical complexity. Travel and accommodation are not included.

For most patients from Jakarta, Surabaya, Ho Chi Minh City, and Hanoi, China offers the best combination of product access, cost, and direct-flight connectivity — under 6 hours from most Indonesian and Vietnamese hubs to Shanghai, Beijing, or Guangzhou.


Step-by-Step Path: From Indonesia / Vietnam to CAR-T in China

Step 1 — Records Preparation (Weeks 1-2)

What to gather before contacting a Chinese hospital:

  • Recent (within 3 months) pathology report confirming your cancer type and stage
  • Target antigen status — this is the most important document:
    • CD19 for B-cell lymphoma (DLBCL, follicular, mantle cell) and B-cell ALL
    • BCMA for multiple myeloma
    • Claudin18.2 for gastric or gastroesophageal junction (GEJ) adenocarcinoma (satri-cel pathway)
  • Recent imaging (PET-CT or CT) and ECOG performance status
  • Prior treatment lines summary
  • Recent blood work (CBC, liver / kidney function, coagulation)

Tip: Bahasa Indonesia and Vietnamese pathology reports need certified English translation. We provide a free translation checklist for medical records.

STEP 2

Free Eligibility Review (48 hours)

Send your records to our coordination team. We route your case to the right hematology / oncology center — typically Ruijin Hospital (Shanghai) for hematologic CAR-T, or Peking University Cancer Hospital / Jiahui International Hospital (Beijing / Shanghai) for satri-cel (solid tumor).

You receive a written preliminary eligibility response within 48 hours, plus a list of commercial and trial pathways available for your antigen status.

STEP 3

Hospital Issues Medical Visa Invitation Letter

Once you choose a commercial or trial pathway, the hospital issues an official invitation letter on hospital letterhead. This is the document your local Chinese embassy / consulate needs to issue the M (Medical) visa.

Processing time: 5-7 working days at the hospital, 4-7 working days at the embassy. Total: ~2 weeks.

Visa-Free Entry for Indonesian and Vietnamese Patients

As of mid-2026, China has expanded unilateral visa-free entry. Check the table below — if you qualify, you can skip the M-visa application and book flights immediately after hospital confirmation.

NationalityVisa-Free Policy (as of July 2026)Recommended Visa
🇮🇩 Indonesia30-day visa-free entry for tourism / business / family visit. Medical treatment requires M visa — but you can enter visa-free for the hospital consultation and convert to M visa in-country if needed.M visa (medical)
🇻🇳 Vietnam30-day visa-free entry for tourism / business. Same rule: medical treatment requires M visa, but visa-free consultation is allowed.M visa (medical)

The visa-free entry is useful for the initial in-person consultation, but for an apheresis + 4-6 week inpatient stay, the M visa (which allows 30-180 day stays with multiple entries) is the correct route. Hospital invitation letters are the key document.

Step 4 — Travel and Pre-Admission

Direct flight routes from Indonesia / Vietnam to CAR-T centers:

FromToFlight TimeFrequency
Jakarta (CGK)Shanghai (PVG)~7 hoursDaily
Jakarta (CGK)Beijing (PEK)~7.5 hoursDaily
Jakarta (CGK)Guangzhou (CAN)~5 hoursDaily
Ho Chi Minh (SGN)Shanghai (PVG)~4.5 hoursDaily
Ho Chi Minh (SGN)Beijing (PEK)~5 hoursDaily
Ho Chi Minh (SGN)Guangzhou (CAN)~3.5 hoursDaily
Hanoi (HAN)Shanghai (PVG)~4 hoursDaily
Hanoi (HAN)Guangzhou (CAN)~3 hoursDaily

Halal food is available at all listed hospitals and surrounding hotels. Bahasa Indonesia and Vietnamese translators can be arranged through the international patient department with 5-7 days notice.

Step 5 — Apheresis, Manufacturing, Infusion, Monitoring (4-6 weeks)

PhaseDurationWhat Happens
Pre-admission tests2-3 daysImaging, blood work, cardiac echo, infectious disease screening
Apheresis (T-cell collection)1 dayOutpatient; ~3-4 hours hooked up to cell-separator machine
CAR-T manufacturing2-4 weeksYour T cells are shipped to a cGMP facility, modified, expanded, quality-tested
Lymphodepleting chemotherapy3-5 daysInpatient; fludarabine + cyclophosphamide
CAR-T infusion1 daySingle IV infusion; takes 15-30 minutes
Inpatient monitoring10-14 daysDaily blood work, CRS / ICANS surveillance, infection prevention

Step 6 — Discharge and Return Home

Discharge with 30-day medication plan and 24-hour emergency contact. Most international patients fly home 14-21 days post-infusion (after blood counts recover).

Local follow-up plan (handled by your home oncologist):

  • Weekly CBC for the first month
  • Monthly blood work and cytokine panel for 3 months
  • PET-CT or MRI at 3, 6, and 12 months
  • Tele-consult with the China team at 1, 3, 6, and 12 months

Total Budget for Indonesian / Vietnamese CAR-T Patients (2026)

ItemEstimated Cost (USD)
CAR-T commercial (hematologic)$89K – $130K
CAR-T commercial (satri-cel, solid tumor)$89K – $170K
OR CAR-T clinical trial (eligible patients)$30K – $80K
Round-trip flights (Jakarta / HCMC / Hanoi → China)$400 – $900
Companion accommodation (4-6 weeks)$1,200 – $3,000
Hospital deposit (typically 50%)Variable
Visa fees (if M visa needed)$0 – $140
Translator / coordinator$300 – $1,500
Post-treatment follow-up scans (3 / 6 / 12 months)$1,000 – $3,000
Total trip (excluding CAR-T)$3,000 – $8,500

For trial access, total cost is typically $33K – $88K all-in. For commercial hematologic CAR-T, total cost is typically $92K – $138K. These figures assume 1 companion traveling with the patient.


Frequently Asked Questions

Do Indonesian and Vietnamese patients need a visa for CAR-T in China?

Most patients need an M (Medical) visa, which requires a hospital invitation letter. Indonesia and Vietnam are eligible for 30-day visa-free entry for tourism / business, but for a 4-6 week CAR-T stay the M visa is the correct route. Hospital invitation letters are issued within 5-7 working days. (As of mid-2026; check the Chinese embassy for the latest rules.)

Which Chinese hospital is best for CAR-T for an Indonesian patient?

For hematologic CAR-T (lymphoma, leukemia, multiple myeloma): Ruijin Hospital, Shanghai — top hematology program in China with 300+ CAR-T infusions annually and direct flights from Jakarta (CGK) daily. For satri-cel (Claudin18.2, gastric cancer): Jiahui International Hospital, Shanghai or Peking University Cancer Hospital, Beijing — both commercial launch sites with international-standard care. Jiahui has the strongest international patient infrastructure (English / Arabic / Bahasa Indonesia translators).

Is Bahasa Indonesia or Vietnamese support available at Chinese hospitals?

Yes — at Jiahui International Hospital (Shanghai) and the international departments of Ruijin / Peking University Cancer Hospital, Bahasa Indonesia and Vietnamese translators can be arranged with 5-7 days notice. Halal meals are available at all listed hospitals. For trial-based access, translator coordination is typically included in the trial sponsor's logistics package.

How long does the full CAR-T process take in China for an Indonesian patient?

From hospital confirmation to discharge: 4-6 weeks in China. Add 2-3 weeks before for visa, travel, and pre-admission scheduling. Add 30-60 days after for local follow-up. Total end-to-end timeline: ~10-14 weeks from decision to local recovery. Compared to Singapore (similar timeline but 2-3x higher cost), China offers the most cost-effective option for Indonesian and Vietnamese patients.

Are there clinical trials that reduce the cost of CAR-T for Indonesian patients?

Yes — clinical trial access can drop the CAR-T product cost to $30,000 – $80,000. Eligibility depends on antigen status (CD19, BCMA, Claudin18.2), prior treatment lines, ECOG performance, and organ function. Trial slots are most available for Claudin18.2 (gastric, common in East / Southeast Asian populations), CD19 (relapsed DLBCL, ALL), and BCMA (multiple myeloma). Bahasa Indonesia consent documents are available for major trials.


Related Reading